Author + information
- Received July 29, 2014
- Revision received September 18, 2014
- Accepted September 21, 2014
- Published online December 16, 2014.
- Robert S. Rosenson, MD∗∗ (, )
- Michael H. Davidson, MD†,
- Benjamin J. Hirsh, MD‡,
- Sekar Kathiresan, MD§ and
- Daniel Gaudet, MD, PhD‖
- ∗Mount Sinai Heart, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York
- †Division of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, Illinois
- ‡Mount Sinai Heart, Mount Sinai Hospital, New York, New York
- §Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- ‖ECOGENE-21 and Lipid Clinic, Department of Medicine, Université de Montreal, Chicoutimi, Quebec, Canada
- ↵∗Reprint requests and correspondence:
Dr. Robert S. Rosenson, Mount Sinai Heart, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York 10029.
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This “omic” approach recently resulted in new targets for reducing CVD events.
Dr. Rosenson’s institution has received research grants from Amgen, AstraZeneca, and Sanofi; he serves on the advisory boards of Aegerion, Amgen, AstraZeneca, Eli Lilly and Company, Regeneron, and Sanofi; serves as a consultant to Novartis and Sanofi; has received an honorarium from Kowa; holds stock in and has received a travel award from LipoScience, Inc.; and has received royalties from UpToDate, Inc. Dr. Davidson has served as a consultant to Amgen, AstraZeneca, Merck & Co., and Sanofi; and is employed by Omthera, a fully owned subsidiary of AstraZeneca. Dr. Kathiresan has served as a consultant to Aegerion, Amgen, Novartis, Eli Lily and Company, Catabasis, and Regeneron; has served on the scientific advisory board of Catabasis and Regeneron; and has received research grants from AstraZeneca, and Merck & Co. Dr. Gaudet serves on the advisory boards of Aegerion, Amgen, Catabasis, Isis, Regeneron, Sanofi, and Uniqure; and is a consultant to Chiesi, Novartis, and Regeneron. Dr. Hirsh has reported that he has no relationships relevant to the contents of this paper to disclose. Moti Kashyap, MD, served as Guest Editor for this paper.
- Received July 29, 2014.
- Revision received September 18, 2014.
- Accepted September 21, 2014.
- American College of Cardiology Foundation
- TGRL, Human Atherosclerosis, and Atherosclerotic Cardiovascular Events
- Metabolism of Intestinal and Hepatic-Derived TGRLs
- Physiology of Post-Prandial Lipemia: Cardiovascular Risk of Fasting Versus Nonfasting Triglyceride Measurement
- Atherogenicity of TGRL Cholesterol
- Non-HDL-C, Apolipoprotein B, and LDL Particle Concentration as Targets of Therapy for the Prevention of Atherosclerosis and Atherosclerotic CVD
- TGRLs: Lessons From Human Genetics
- Recent Advances in the Genetics and Therapeutic Benefits of Currently Available TG-Lowering Drugs
- Omega-3s for Management of Hypertriglyceridemia
- FADS Polymorphisms and Plasma Levels of Omega-3 Fatty Acids
- Biological Differences in EPA, DHA, and DPA
- Emerging Therapies for Management of Hypertriglyceridemia